DrugPatentWatch Database Preview
NORMOCARB HF 25 Drug Profile
» See Plans and Pricing
When do Normocarb Hf 25 patents expire, and when can generic versions of Normocarb Hf 25 launch?
Normocarb Hf 25 is a drug marketed by Dialysis Sups and is included in one NDA. There is one patent protecting this drug.
This drug has four patent family members in four countries.
The generic ingredient in NORMOCARB HF 25 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.
DrugPatentWatch® Generic Entry Outlook for Normocarb Hf 25
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 4, 2023. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NORMOCARB HF 25
International Patents: | 4 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NORMOCARB HF 25 at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for NORMOCARB HF 25
Generic Entry Date for NORMOCARB HF 25*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for NORMOCARB HF 25
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dialysis Sups | NORMOCARB HF 25 | magnesium chloride; sodium bicarbonate; sodium chloride | SOLUTION;INJECTION | 021910-001 | Jul 26, 2006 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NORMOCARB HF 25
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Dialysis Sups | NORMOCARB HF 25 | magnesium chloride; sodium bicarbonate; sodium chloride | SOLUTION;INJECTION | 021910-001 | Jul 26, 2006 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NORMOCARB HF 25
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2620902 | Start Trial |
Canada | 2365787 | Start Trial |
World Intellectual Property Organization (WIPO) | 0249693 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NORMOCARB HF 25
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0984957 | 122012000051 | Germany | Start Trial | PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
1020461 | C300482 | Netherlands | Start Trial | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105 |
0984957 | CR 2012 00035 | Denmark | Start Trial | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |